Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma - Top-Institutions - MDSpire

Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma

By
F. Schwarz
L. Levien
M. Maulhardt
G. Wulf
N. Brökers
E. Aydilek
February 3, 2026
0 min

Npj Digital Medicine

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Mayo Clinic

Rochester, MN
Key Differentiators
- Hematology
- Oncology
- Stem Cell Transplantation
#2

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Hematology
- Oncology
- Stem Cell Transplantation
#3

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Hematology
- Oncology
- Stem Cell Transplantation
#4

University Medical Center Göttingen

Göttingen, Lower Saxony
Key Differentiators
- Hematology
- Oncology
- Stem Cell Transplantation
#5

Fred Hutchinson Cancer Center

Seattle, WA
Key Differentiators
- Hematology
- Oncology
- Stem Cell Transplantation

Original Source(s)

Npj Digital Medicine

Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma

by F. Schwarz, L. Levien, M. Maulhardt, G. Wulf, N. Brökers, E. Aydilek
February 3, 2026

Related Content

The Medicine Maker

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

March 31, 2026
2 min

Frontiers In Oncology

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

by Jirui Zhong, Xikun Liu, Jiduo Liu, Shanshan Xiao, Xuekui Gu, Zenghui Liu
April 22, 2026

Frontiers In Immunology

Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders